2-[3,5-dichloro-4-[[3-(1-phenylethyl)-1H-indol-5-yl]oxy]phenyl]-6-methyl-1,2,4-triazine-3,5-dione
C26H20Cl2N4O3 — CID 155720257
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[3,5-dichloro-4-[[3-(1-phenylethyl)-1H-indol-5-yl]oxy]phenyl]-6-methyl-1,2,4-triazine-3,5-dione
2-[3,5-dichloro-4-[[3-(1-phenylethyl)-1H-indol-5-yl]oxy]phenyl]-6-methyl-1,2,4-triazine-3,5-dione (PubChem CID 155720257) has the molecular formula C26H20Cl2N4O3 and a molecular weight of 507.38 g/mol. Its IUPAC name is 2-[3,5-dichloro-4-[[3-(1-phenylethyl)-1H-indol-5-yl]oxy]phenyl]-6-methyl-1,2,4-triazine-3,5-dione.
Molecular Properties
| Compound Name | 2-[3,5-dichloro-4-[[3-(1-phenylethyl)-1H-indol-5-yl]oxy]phenyl]-6-methyl-1,2,4-triazine-3,5-dione |
|---|---|
| PubChem CID | 155720257 |
| Molecular Formula | C26H20Cl2N4O3 |
| Molecular Weight | 507.38 g/mol |
| Exact Mass | 506.09 |
| IUPAC Name | 2-[3,5-dichloro-4-[[3-(1-phenylethyl)-1H-indol-5-yl]oxy]phenyl]-6-methyl-1,2,4-triazine-3,5-dione |
| SMILES | Cc1nn(-c2cc(Cl)c(Oc3ccc4[nH]cc(C(C)c5ccccc5)c4c3)c(Cl)c2)c(=O)[nH]c1=O |
| InChI | InChI=1S/C26H20Cl2N4O3/c1-14(16-6-4-3-5-7-16)20-13-29-23-9-8-18(12-19(20)23)35-24-21(27)10-17(11-22(24)28)32-26(34)30-25(33)15(2)31-32/h3-14,29H,1-2H3,(H,30,33,34) |
| InChIKey | ZFYZYYUEKRZBNM-UHFFFAOYSA-N |
| XLogP | 5.96 |
| TPSA | 92.77 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 507.38 |
| LogP ≤ 5 | 5.96 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155720257 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.